Fate Therapeutics Inc (FATE) saw an uptrend of 1982664% in the recent trading with $2069999.9999999998 being its most recent. The current price level -81.42% lower than the highest price of $5.92 marked by the stock while trading over the past 52-weeks, whereas it is 66.40% higher than the lowest price of $0.66 the company dropped to over past 52-weeks. The latest news story on FATE appeared in (Zacks) under the title “Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?” on Jun-12-25.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 8 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.30 for the stock.
Fate Therapeutics Inc Earnings – What Happened With FATE
Coming around sales and income figures on FATE Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Fate Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 114.60 million. FATE does have institutional investors; and they hold 84.23% of the stock.
As on 2024-06-30, REDMILE GROUP, LLC was the top most holder in Fate Therapeutics Inc (NASDAQ:FATE) with an ownership of 13.17 million shares of the company or 11.2107 of the stake worth $43.19 million. The filing also reveals VANGUARD GROUP INC as the second largest holder in the company with a control over 8.998 of the outstanding shares. Its stake is worth $34.67 million for having 10.57 million shares in hand.
BLACKROCK INC. also came holding a key position in the company during the recent quarter and it now holds 8.6118 of the outstanding shares. With this there are now 182.0 institutions which have possession in FATE’s shares.
Key Metrics forFATE
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Fate Therapeutics Inc has a debt to equity ratio of 0.29.
Technical Analysis of Fate Therapeutics Inc (NASDAQ:FATE) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Fate Therapeutics Inc (FATE), we notice that the stock’s 20-day average volume is at 2,052,155 shares. Medium term indicators at an average of 50% are spotting the stock at Sell with its 50-day average volume of 1,986,778 shares. And to end, FATE’s 100-day average volume is 2,198,389 shares with 100% of the long-term indicators pointing towards Sell for the stock.
